YOLFTbeta
68

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A

688221 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

13.17CNY-0.45 (-3.30%)

Price History

Full chart

Market Stats

Previous Close13.62
Open13.63
Day Range13.12 – 13.73
52-Week Range13.06 – 29.98
Volume6.02M
Market Cap6.32B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.06
Dividend Yield0.00%
Beta0.89
50-Day Avg18.56
200-Day Avg20.84

About

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company's pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Dong Xie Ph.D.
  • Employees265
  • HeadquartersBuilding E-2, Greenland Window, Nanjing, China, 211199, China
  • Websitehttps://www.frontierbiotech.com

Leadership

  • Dr. Dong Xie Ph.D.Founder, Chairman, President & Chief Scientific Officer · b. 1966
  • Mr. Qi ShaoSenior VP, COO & CFO · b. 1980
  • Dr. Rongjian Lu Ph.D.CTO & Director · b. 1962
  • Mr. Hangzhou LvSenior Vice President of Marketing & Sales · b. 1970
  • Dr. Changjin Wang Ph.D.MD, CBO & Director · b. 1958
  • Ms. Qianya GaoVP, Deputy GM & Secretary of the Board of Directors · b. 1986
  • Xin GuanAccounting Supervisor
  • Michael HuC.M.O.
  • Michael WangSenior Vice President & Head of Infectious Diseases Therapy Area

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue20.86M46.62M40.50M84.74M114.25M129.47M123.39M
Growth (%)-+123.50%-13.13%+109.22%+34.82%+13.32%-4.70%
Cost of Revenue31.26M38.04M52.83M68.97M81.12M85.55M82.40M
Gross Profit-10.40M8.59M-12.33M15.77M33.13M43.93M40.99M
Gross Margin-49.87%18.42%-30.44%18.61%29.00%33.93%33.22%
Operating Expense169.49M245.27M300.15M390.62M363.64M275.56M282.01M
Operating Income-179.90M-236.69M-312.48M-374.86M-330.52M-231.64M-241.02M
Operating Margin-862.40%-507.66%-771.51%-442.36%-289.29%-178.91%-195.34%
EBITDA-156.12M-195.97M-219.69M-300.74M-275.14M-149.29M-215.92M
EBITDA Margin-748.40%-420.32%-542.41%-354.90%-240.82%-115.30%-174.99%
Net Income-192.45M-230.73M-260.06M-356.76M-328.96M-201.38M-268.05M
Net Income Margin-922.58%-494.89%-642.07%-421.01%-287.93%-155.54%-217.25%
R&D85.42M138.49M172.11M274.33M214.23M137.21M141.54M
R&D as % of Total Revenue409.50%297.05%424.93%323.73%187.51%105.97%114.71%
Interest Expense899.12K1.36M1.53M4.75M8.47M10.36M9.12M
Interest Expense % of Total Revenue4.31%2.93%3.79%5.60%7.41%8.00%7.39%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets939.53M2.53B2.53B2.41B2.14B1.81B1.58B
Total Liabilities336.54M384.69M702.41M739.41M797.44M670.83M701.44M
Total Equity602.83M2.14B1.83B1.67B1.34B1.14B876.87M
Cash227.39M839.09M800.85M550.89M526.66M248.98M170.34M
Net Debt-----114.35M162.22M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow34.29M-170.17M-243.07M-289.04M-267.17M-172.52M-226.59M
Capital Expenditure160.50M186.41M327.15M140.37M129.35M18.60M29.86M
Free Cash Flow-126.21M-356.59M-570.22M-429.42M-396.52M-191.12M-256.45M
Dividends Paid850.09K1.36M5.54M15.13M14.46M14.91M8.19M
FCF to OCF-368.10%209.54%234.59%148.57%148.41%110.78%113.18%
Dividend Paid to FCF-0.67%-0.38%-0.97%-3.52%-3.65%-7.80%-3.20%

Earnings

Report DateApr 28, 2021Aug 16, 2021Oct 15, 2021Feb 25, 2022Apr 29, 2022Aug 30, 2022Oct 25, 2022Mar 30, 2023Apr 28, 2023
EPS Estimate--0.19-0.23-0.25--0.37-0.44-0.37-
EPS Actual-0.12-0.13-0.26-0.29-0.16-0.18-0.29-0.40-0.35
Surprise-31.58%-13.04%-16.00%-51.35%34.09%-8.11%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap6.32B
Enterprise Value6.26B
Trailing P/E0.00
Forward P/E0.00
Price / Sales16.72
Price / Book6.33
EPS-0.06
Book Value2.76
Revenue (TTM)378.04M
Gross Profit (TTM)281.47M
EBITDA-15.16M
Profit Margin-5.76%
Operating Margin-579.17%
Return on Equity-2.10%
Return on Assets-1.20%
Shares Outstanding374.58M
Shares Float219.38M
Beta0.89
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%